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Developing drug-like molecules to inhibit the interactions formed by disordered proteins
is desirable due to the high correlation of disorder with protein implicated in disease, but
is challenging due in part to the lack of atomistically resolved and resolvable structures
from conformationally dynamic systems. Ion mobility mass spectrometry (IM-MS) is
well-positioned to assess protein ligand interactions along with the effect of a given
inhibitor on conformation. Here we demonstrate the use of IM-MS to characterize the
effect of two inhibitors RITA and Nutlin-3 on their respective binding partners: p53 and
MDM2. RITA binds N-terminal transactivation domain of p53 (Np53) weakly, preventing
direct observation of the complex in the gas phase. Nonetheless, upon incubation with
RITA, we observe an alteration in the charge state distribution and in the conformational
distributions adopted by Np53 in the gas phase. This finding supports the hypothesis that
RITAs mode of action proceeds via a conformational change in p53. Circular dichroism
corroborates our gas phase findings, showing a slight increase in secondary structure
content on ligand incubation, and HDX-MS experiments also highlight the dynamic
properties of this protein. Using the same approach we present data to show the effect
of Nutlin-3 binding to the N-terminal domain of MDM2 (N-MDM2), N-MDM2 presents as
at least two conformational families in the absence of Nutlin-3. Upon Nutlin-3 binding,
the protein undergoes a compaction event similar to that exhibited by RITA on Np53.
This multi-technique approach highlights the inherent disorder in these systems; and in
particular exemplifies the power of IM-MS as a technique to study transient interactions
between small molecule inhibitors and intrinsically disordered proteins.
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Introduction
The transcription factor p53, dubbed the Death Star (Vousden,
2000), is a multi-domain, intrinsically disordered protein (IDP)
(Bell et al., 2002; Dawson et al., 2003). The protein comprises the
disordered N-terminal domain (Np53) (Joerger and Fersht, 2008)
containing the transactivation domain (residues 1–61) and the
proline-rich domain (residues 62–94), the central DNA binding
domain (residues 94–292), the tetramerization domain (residues
325–355) and the C-terminal regulatory domain (residues 363–
393). It is strongly implicated in tumor suppression pathways,
where it functions to block tumor development by triggering
cellular senescence or apoptosis upon signals indicating DNA
damage, oncogene activation, or telomere erosion (Vousden and
Prives, 2009). Under non-stressed conditions, low p53 levels are
tightly maintained by MDM2 (murine double minute 2). MDM2
is a ∼55KDa IDP with roles as an Ubiquitin E3 ligase, as a
molecular chaperone and also in translational control. MDM2
comprises the disordered “lid” mini-domain (residues 1–24),
(Uhrinova et al., 2005) the N-terminal domain (residues 25–
109), the disordered central acidic domain (residues 221–276),
the zinc finger domain (residues 299–331), and the C-terminal
RING (really interesting new gene) domain (residues 430–480).
MDM2 down regulates p53 activity in a negative autoregulatory
feedback loop via three mechanisms; firstly, MDM2 blocks the
transcription ability of p53 by direct binding through their
respective N-terminal domains (Wu et al., 1993; Haupt et al.,
1997). Secondly, MDM2 exports p53 from the nucleus and
thirdly, targets p53 by Ubiquitination for degradation via the
proteasome (Freedman and Levine, 1998; Tao and Levine, 1999).
p53 N-terminal domain binds into the MDM2 N-terminal
domain hydrophobic pocket as an amphipathic helix, with
residues Ph19, Trp23, and Leu26 comprising a triad of required
contacts which insert into the MDM2 binding cleft (Kussie et al.,
1996).
Alteration of the p53 pathway is an almost universal hallmark
of human cancers, with 22 million cancer patients living with
abrogation of the p53 pathway, half of which display suppressed
p53 function (Brown et al., 2009) and half of which exhibit
p53 mutations. Cellular overexpression of MDM2 effectively
abolishes p53 function, allowing unregulated cell cycle events in
tumor cells. Inhibition of the p53:MDM2 complex is therefore a
highly desirable therapeutic strategy; releasing, reactivating and
stabilizing p53 levels, thus providing an attractive cancer therapy
drug target. To date, numerous p53:MDM2 protein–protein
interaction (PPI) antagonists have been identified, including cis-
imidazolines (Vassilev et al., 2004; Vu et al., 2013), “stapled”
peptides (Brown et al., 2012; Chang et al., 2013), terphenyls
(Yin et al., 2005), oligobenzamides (Lu et al., 2006), spiro-
oxindoles (Ding et al., 2006), chromenotriazolopyrimidine (Rew
et al., 2012), Benzodiazepinedione (Grasberger et al., 2005),
and Chromenotriazolopyrimidines (Allen et al., 2009). The cis-
imidazoline Nutlin-3 is composed of enantiomers a and b,
of which enantiomer a is 150 times more potent, and binds
MDM2 in the p53 peptide groove, mimicking the three p53
residues responsible for the bulk of binding interactions (Vassilev
et al., 2004). Nutlin-3 is effective in numerous cell lines, and is
able to arrest or induce apoptosis in proliferating cancer cells
with micromolar concentrations (Tovar et al., 2006). The drug
candidate RITA (reactivation of p53 and induction of tumor cell
apoptosis, NSC 652287) has been shown to restore wild-type p53
function in tumor cells by preventing the p53:MDM2 interaction
(Issaeva et al., 2004). In contrast to the Nutlins, which bind
MDM2 in its N-terminal hydrophobic pocket (Vassilev et al.,
2004), RITA binds to p53 N-terminal domain with estimated
KD = 1.5 nM. It is hypothesized that RITA binds outside of the
p53/MDM2 binding cleft, allosterically exerting its effect via a
conformational change in the highly disordered N-terminus of
p53 (Np53) (Issaeva et al., 2004).
Since its advent in the 1970’s (Hogg and Kebarle, 1965; Kebarle
and Hogg, 1965), the hybrid gas phase technique Ion Mobility-
Mass Spectrometry (IM-MS) has gained credibility as a tool to
study the conformations adopted by proteins and peptides in the
gas phase. IM-MS is especially effective in its use for studying
IDPs (Bernstein et al., 2004; Harvey et al., 2012; Pagel et al., 2013)
due to its ability to observe conformations adopted by analytes
on amillisecond time scale (Wyttenbach et al., 2001; McCullough
et al., 2008). IM-MS provides information regarding charge, mass
and shape of an analyte. The simplest setup of IM-MS is that
of drift time IM-MS (DT IM-MS) (McAfee and Edelson, 1963).
Ions are separated by their mobility (K) as they traverse a drift
cell of known length filled with buffer gas to a known pressure
and temperature. Ions travel down a weak electric field (5–50V
cm−1) colliding with buffer gas molecules which counter their
progress until an equilibrium drift velocity, proportional to the
electric field, is reached. The mobility (K) of an ion is the ratio
between the drift velocity (vd) and the applied electric field (E).
The mobility of an ion can be used to calculate the rotationally
averaged collision cross section (CCS, , Å2) using Equation (1)
(Mason and McDaniel, 2005):
K0 =
3ze
16N
(
2pi
µkBT
)0.5 1

(1)
WhereK0 is the reducedmobility; z is the ion charge state; e is the
elementary charge; N is the gas number density; µ is the reduced
mass of the ion-neutral pair; kB is the Boltzmann constant, and T
is the gas temperature.
Here we employ native mass spectrometry, DT IM-MS,
circular dichroism (CD) and hydrogen-deuterium exchange
coupled to mass spectrometry (HDX-MS) to observe the
conformations of N-terminal p53 domain (Np53) and the N-
terminal domain of MDM2 (N-MDM2) both in the gas phase
and in solution. We also probe the binding and conformational
changes conferred by small molecule inhibitors; Nutlin-3 for
N-MDM2, and RITA for Np53. Further information about DT
IM-MS, CD and HDX-MS methodology can be found in the
Supporting Information.
Materials and Methods
Expression and purification of both Np53 (residues 1–100)
(Szekely et al., 1993; Bakalkin et al., 1995) and N-MDM2
(residues 1–126) (Worrall et al., 2010) have been previously
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described. Before the analysis reported here, the protein
samples were thawed and dialysed in 50mM ammonium
acetate using Bio-RADmicro bio-spin chromatography columns
(Bio-Rad Laboratories, Inc.). Concentrations of purified
proteins were measured by the Thermo Scientific NanoDrop
Spectrophotometer ND 1000 (Thermo Scientific, USA). Small
molecule RITA [2,5-bis(5-hydroxymethyl-2-thienyl) furan, NSC
652287] was reconstituted in 100% IPA and stored at −20◦C.
Before analysis, RITA was thawed and diluted to 100µM and
an IPA concentration of 5% using 50mM ammonium acetate.
Nutlin-3 was reconstituted in 100% DMSO and stored at−80◦C.
Before analysis, Nutlin-3 was thawed and diluted to 500µM and
a DMSO concentration of 1% using 50mM ammonium acetate.
MS and IM-MS experiments were performed on Np53 and
N-MDM2 from solutions buffered with ammonium acetate (pH
6.8). Np53 samples were incubated with 5% IPA for 30min at
37◦C to account for the solvent present in the RITA sample. N-
MDM2 samples were incubated with 0.5% DMSO for 30min
at room temperature to account for the solvent present in the
Nutlin-3 sample. Binding experiments were performed on Np53
with RITA in a 1:2 protein:ligand ratio, samples were incubated
for 30min at 37◦C. Binding experiments were performed on
N-MDM2 and Nutlin-3 in a 1:10 protein:ligand ratio, samples
were incubated for 30min at room temperature. All MS and DT
IM-MS data were acquired on an in-house modified quadropole
time-of-flight mass spectrometer (Waters, Manchester, UK)
(McCullough et al., 2008) containing a copper drift cell of
length 5.1 cm. Ions were produced by positive nano-electrospray
ionization (nESI) with a spray voltage of 1.3–1.62 kV. Heliumwas
used as the buffer gas, its pressure measured using a baratron
(MKS Instruments, UK). Buffer gas temperature and pressure
readings (294.31–303.69K and 3.518–3.898 Torr, respectively)
were taken at each drift voltage and used in the analysis of drift
time measurements. The drift voltage across the cell was varied
by decreasing the cell body potential from 60 to 15V, with arrival
time measurements taken at a minimum of five distinct voltages.
Instrument parameters were kept as constant as possible and are
as follows: cone voltage: 114–119V, source temperature: 80◦C.
nESI tips were prepared in-house using a micropipette puller
(Fleming/Brown model P-97, Sutter Instruments Co., USA)
using 4′′ 1.2mm thin wall glass capillaries (World Precision
Instruments, Inc., USA) and filled with 10–20µL of sample.
Data was analyzed using MassLynx v4.1 software (Waters,
Manchester, UK), Origin v9.0 (OriginLab Corporation, USA)
and Microsoft Excel. Experiments were carried out in triplicate.
Ion arrival time distributions were recorded by synchronization
of the release of ions into the drift cell with mass spectral
acquisition. The collision cross section distributions (CCSD) are
derived from arrival time data using Equation (2) (Mason and
McDaniel, 2005):
avg =
(18pi)1/2
16
[
1
mb
+
1
m
]1/2 ze
(KBT)
1/2
1
ρ
tdV
L2
(2)
Where  is the collision cross section (Å2); m and mb are the
masses of the ion and buffer gas, respectively; z is the ion charge
state; e is the elementary charge; kB is the Boltzmann constant;
T is the gas temperature; ρ is the buffer gas density; L is the drift
tube length;V is the voltage across the drift tube; and td is the drift
time. For these experiments where the CCS has been evaluated
experimentally with helium as the buffer gas and using a drift
tube with a linear field we use the convention DTCCSHe to report
our collision cross section values in the context of the mobility
technique employed as well as the buffer gas used.
HDX-MS experiments were carried out using a fully
automated LEAP autosampler system (HTS PAL, Leap
Technologies, Carrboro, NC, USA) previously described
(Chalmers et al., 2006; Zhang et al., 2009) and an online Acquity
UPLC M-class HDX System (Waters Inc., Manchester, UK).
Np53 and RITA were mixed at a 1:2 protein:ligand ratio and
incubated for 30min at 37◦C before analysis. Stock protein
solutions (50µM Np53 ± 100µM RITA, with 5% IPA) were
diluted to 10µM with equilibration buffer. 3.8µl protein
solution was incubated with D2O (54.2µl labeling buffer) and
incubated at 18◦C for 15, 30, 60, or 120 s. Following deuterium
on-exchange, 50µl of the labeled protein solution was quenched
by adding 50µl of quench buffer at 1◦C, and samples were passed
across an immobilized pepsin column (enzymate BEH pepsin
column, Waters Inc., Manchester, UK) at 100µL min−1 (H2O
+ 0.1% formic acid, 20◦C). The resulting peptides were trapped
on a UPLC BEH C18 Van-Guard Pre-column (Waters Inc.,
Manchester, UK) and then gradient eluted (1min loading time,
8–85% ACN + 0.1% formic acid gradient, 40µl min−1, 1◦C)
across a UPLC BEH C18 column (Waters Inc., Manchester, UK)
before undergoing electrospray ionization and analysis using a
Synapt G2Si mass spectrometer (Waters Inc., Manchester, UK).
Data was analyzed using ProteinLynx Global Server (PLGS)
(Waters, Manchester, UK), Dynamx v1.0 (Waters, Manchester,
UK) and Origin v9.0 (OriginLab Corporation, USA).
Hundred percentage of sequence coverage was obtained for
Np53 ± RITA. Selected peptides were restricted to be present in
all three repeats of 0 s incubation time experiments.
Results
Modulation of N-terminal p53 by RITA
In the absence of RITA and under near neutral solution pH
conditions, the mass spectra of Np53 (Figure 1A) presents
a broad monomeric charge state distribution (CSD) range
5 ≤ z ≤ 12, with three major signals corresponding to the ions
[M+6H]6+, [M+7H]7+, and [M+8H]8+, of which the
[M+6H]6+ species is most intense. Upon incubation of Np53
with RITA we observe a shift in the CSD toward lower charge
states. Specifically, Np53 in the presence of RITA (Figure 1B)
exhibits a significant decrease in intensity of the [M+7H]7+ and
[M+8H]8+ species, along with an increase in the intensity of
the [M+5H]5+ species, an appearance of the [M+4H]4+ species
and a loss of the high charge states z >10. Although source
conditions were carefully controlled to give gentle ionization of
the sample, the Np53:RITA complex was not strong enough to
be retained during desolvation at any protein:ligand ratio (data
not shown).
DT IM-MS was performed on Np53 both in the absence
and presence of RITA. The collision cross section distribution
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FIGURE 1 | n-ESI mass spectra recorded for (A) wild-type Np53 and (B)
wild-type Np53 in the presence of RITA. Np53 was incubated for 30min at
37◦C with addition of 5% IPA. Binding studies were carried out at a 1:2
Np53:RITA ratio, incubated for 30min at 37◦C with 5% IPA content.
(DTCCSDHe) (Figure 2A top panel) shows the Np53 [M+6H]6+
charge state presents as two conformational families; a
more populated compact form (denoted C1, blue Gaussian
distribution) centered at ∼1250 Å2 and a low intensity extended
form (denoted X, green Gaussian distribution) centered at
∼1500 Å2. Two conformations are also observed for [M+7H]7+
(Figure 2B), which are assigned to X and a more intense larger
distribution, centered at ∼1750 Å2, which is assigned to an
unfolded form of the protein (U, purple Gaussian distribution).
[M+8H]8+ (Figure 2C), is also made up of U, along with
low intensity signal from a still more extended form (U2,
gold Gaussian distribution), although this latter distribution
is poorly resolved. [M+9H]9+ (Figure S2) presents in three
conformational families; X, U, and U2, of which the most
extended U2 is most populated.
Upon incubation with RITA the DTCCSDHe for [M+6H]6+
is significantly altered (Figure 2A bottom panel); we no longer
observe the extended conformer X, observe a reduction in
the population of compact conformer C1, and the induction
of a highly populated novel conformational family centered
at ∼950 Å2, C0 (red Gaussian distribution). The [M+7H]7+
CCSD (Figure 2B) is also altered by the presence of RITA, with
loss of conformer U, and induction of both conformers C1
and C0. This change is accompanied by a decrease in intensity
of this charge state. [M+8H]8+ (Figure 2C) behaves similarly
to [M+7H]7+, with loss of conformer U2, and induction of
conformers X and C1. We observe an increase in the intensity
of the [M+5H]5+ species (Figure S1) along with the appearance
of a highly compact form of the protein C0. This compaction
is evident in all charge states, for example [M+9H]9+ (Figure
S2) has lost the population of the unfolded conformer U2 upon
incubation with RITA, alongside a reduction in intensity of
conformers X and U and induction of highly populated C1
conformational family. This alteration of the conformational
spread as shown by the DTCCSDHe is supported in solution by
CD. Figure S3 (Supporting Information) shows the secondary
structure content of Np53 increases upon incubation with RITA,
supporting the hypothesis that RITA induces a novel conformer
of Np53. Structural analysis using DiChroWeb (Lobley et al.,
2002) using CONTILL algorithm (Provencher and Gloeckner,
1981; Sreerama and Woody, 2000) predicted that Np53 is 32%
disordered, and upon incubation with RITA the level of disorder
reduced to 28%.
Hydrogen–deuterium exchange coupled tomass spectrometry
(HDX-MS) was used to ascertain if the conformational changes
induced by RITA could be mapped in the solution phase. Np53
was incubated for varying time points in deuterated buffer,
and the mass shift of peptides was determined. Np53 shows
a significant uptake of deuterium at the shortest experimental
time point of 15 s for a large proportion of peptides detected
(Figures 3A–D). From the mas spectrometry data of each
peptide, we observe no significant difference between deuterium
uptake in the absence or presence of RITA, as shown by the
deuterium uptake curves for selected representative peptides
residues 23–30 and 53–63 (Figures 3E,F, respectively). This
indicates that we cannot sample the interconverting solution
conformations for this highly dynamic protein over the longer
timescale of the HDX-MS experiment. The butterfly plot in
Figure 3G depicts the overall deuterium uptake differences
between Np53 in the absence and presence of RITA. Each set
of points along the x-axis represent a peptide, with time points
denoted by different colored points and lines [15 (yellow), 30
(red), 60 (blue), and 120 (black) s incubation time]. Gray bands
indicate the error in the uptake level and vertical lines indicate the
sum of uptake differences for each time point. Several peptides
show deuterium uptake differences slightly above the error, but
all at <1Da, indicating that this protein is highly dynamic
with or without RITA, for example, the greatest deuterium
uptake difference in Np53 in the absence and presence of RITA
being 0.271Da, for a peptide spanning residues 23–39 with a
[M+2H]2+ charge state.
Modulation of N-terminal MDM2 by Nutlin-3
Mass Spectra for MDM2 (Figure 4A) sprayed from native
conditions with 50mM ammonium acetate and 0.5% DMSO
show a broad bimodal CSD spanning charge states 5 ≤ z ≤ 14.
The most intense species is [M+10H]10+ with significant
intensity also in [M+7H]7+ and [M+6H]6+. We observe low
intensity [D+11H]11+, [D+13H]13+, and [D+15H]15+ dimers,
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FIGURE 2 | Collision cross section distributions (DTCCSDHe) arising
from arrival time distributions (ATDs) at drift voltage 35V for Np53 in
the absence (top panels) and presence (bottom panels) of RITA.
Distributions shown for the (A) [M+6H]6+ (B) [M+7H]7+, and (C) [M+8H]8+
species. In the absence of RITA, Np53 was incubated with 5% IPA for 30min
at 37◦C. Binding studies were carried out at a 1:2 Np53:RITA ratio incubated
at 37◦C for 30min with 5% IPA. DTCCSDHe are normalized to the intensity of
the ion peak in the corresponding mass spectrum. Conformational families
are denoted by hatched Gaussian curves showing novel compact
conformational family C0 in red, compact conformational family C1 in blue,
extended conformational family X in green, and unfolded conformational
family U in purple.
which means that the species attributed to [M+5H]5+ will
also contain some [D+10H]10+ (and the [M+6H]6+ some
[D+12H]12+ etc.) but since the flanking unique m/z dimers
are of an intensity of <5% we ignore this contribution. Upon
incubation with Nutlin-3 (Figure 4B) we see a CSD shift toward
the lower charge states, with the [M+6H]6+ species most intense,
although the CSD range is retained. Binding of one Nutlin-3
molecule to MDM2 is observed at the [M+5H]5+, [M+6H]6+,
and [M+7H]7+ charge states. The shift in the N-MDM2 CSD
upon incubation with Nutlin-3 is substantially greater than that
caused by DMSO alone (Figure S4, Supporting Information)
suggesting that Nutlin-3 confers a structural or conformational
change in N-MDM2.
DT IM-MS analysis reveals that N-MDM2 in the absence
of Nutlin-3 presents as at least two conformational families
at all charge states (Figure S5, Supporting Information). The
[M+5H]5+ charge state (Figure 5A) presents as two conformers
centered at ∼1000 and ∼1250 Å2, referred to as C1 (black
Gaussian curve) and C2 (red Gaussian curve), respectively.
The [M+6H]6+ charge state (Figure 5B) presents as three
conformers, the compact C1 and C2 families and amore extended
family, X (blue Gaussian curve) centered at ∼1400 Å2. The
[M+7H]7+ charge state (Figure 5C) exhibits conformational
family C1 and X and also presents as a large conformer, U
(green Gaussian curve) centered at ∼1700 Å2. Upon binding
to Nutlin-3, we see a change in the DTCCSDHe of N-MDM2
for each charge state. The [M+5H]5+ charge state (Figure 5A,
middle panel) shows retention of the compact conformer C1,
but a significant decrease in the intensity of C2. The [M+6H]6+
charge state, when bound to Nutlin-3, undergoes a compaction
event to produce a single conformational family centered at
∼1250 Å2, corresponding to conformer C2 (Figure 5B, middle
panel). This effect is again seen for the [M+7H]7+ charge state
(Figure 5C, middle panel), which presents as a single conformer
corresponding to conformer X when bound to Nutlin-3. These
altered conformations remain, even when Nutlin-3 is not bound
to N-MDM2. Figure 5 bottom panels show the DTCCSDHe of
N-MDM2 in the presence of Nutlin-3, but not bound in a
complex. The [M+5H]5+ species undergoes a minor change in
the DTCCSDHe with an increase in conformational family C2
compared with the bound complex. Charge states [M+6H]6+
and [M+7H]7+ remain in the single conformational families C2
and X, respectively, even after the ligand is no longer bound.
Discussion
The MS spectra for Np53 in the absence of RITA (Figure 1A)
corroborates previous reports of disorder for the N-terminus of
p53 (Bell et al., 2002; Dawson et al., 2003), a broad charge state
range 5 ≤ z ≤ 12, indicative of a disordered system (Testa et al.,
2011; Beveridge et al., 2014) with numerous residues available for
protonation in solution. We are unable to preserve the binding of
small molecule RITA to Np53, suggesting the binding is lower
affinity than that reported previously (KD = 1.5 nM, Issaeva
et al., 2004) or that it proceeds principally by hydrophobic
interactions that are significantly diminished in the absence of
solvent, resulting in loss of ligand during desolvation.We observe
a narrowing of the CSD for Np53 on ligand incubation, we also
observe the isolated ligand (data not shown), which also supports
our assertion of ligand dissociation during desolvation. This
CSD shift toward lower charge states suggests conformational
tightening induced by RITA, a hypothesis that is supported
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FIGURE 3 | (A,C) Deuterium uptake mass spectra for Np53 peptide
residues 23–30 at time points 0, 15, 30, 60, and 120 s in the absence
(A) and presence (C) of RITA. (B,D) Deuterium uptake charts for Np53
peptide residues 53–63 at time points 0, 15, 30, 60, and 120 s in the
absence (B) and presence (D) of RITA. (E,F) Relative deuterium uptake
plots for Np53 in the absence (black points) and presence (red points) of
RITA for peptide residues 23–30 and 53–63, respectively. (G) Butterfly
plot of uptake difference comparison for Np53 in the absence and
presence of RITA. X-axis denotes each peptide detected, in ascending
residue number. Y-axis denotes uptake difference (Daltons). Colored lines
show uptake difference at 15 (yellow), 30 (red), 60 (blue), and 120 (black)
s incubation time. Gray band indicates the error associated with each
peptide. Vertical lines are the summed difference of all time points for
each peptide.
by DT IM-MS data. The DTCCSDHe for Np53 is significantly
altered in the presence of RITA at all charge states present, with
loss of larger conformational families and induction of more
compact conformers. We observe a compact conformer C0 for
[M+5H]5+, [M+6H]6+, and [M+7H]7+ charge states, which is
not present in the absence of RITA.Whilst the [M+8H]8+species
does not contain any of the C0, it no longer contains conformer
U, rather is populated by the more compact conformers C1
and X, although conformer X is poorly resolved. [M+9H]9+
undergoes loss of conformer U2 with induction of compact
conformer C1 at a much lower DTCCSHe. The use of IM-MS
to discern conformational tightening due to ligand binding has
been previously reported, (Harvey et al., 2012) and along with
these findings provides an exciting prospect as a method for
screening inhibitors to conformationally dynamic systems. As
RITA is predicted to bind outside of the p53:MDM2 hydrophobic
binding pocket (Issaeva et al., 2004), it has been asserted that
the observed inhibition proceeds via a conformational change,
which in turn will allosterically prevent the binding of MDM2.
Our IM-MS data is evidence for the conformational modulation
of Np53 by RITA. The induction of a smaller conformation
is corroborated by CD results, which show an increase in
secondary structure, and a decrease in the disordered content
when analyzed using the CONTILL algorithm. We do note,
however, that the calculated differences in structural content
predictions for Np53 are minimal, with only a 4% decrease
in disordered content, this is less informative than the clear
conformational change provided by IM-MS.
The use of HDX-MS reinforces the view that Np53 is
conformationally dynamic in solution; high levels of deuterium
uptake are observed after 15 s incubation, with very little
further uptake at longer incubation times. This suggests that
backbone amides are solvent exposed and free to exchange with
deuterium. When uptake was compared after RITA incubation
we observe no significant changes in deuterium uptake for Np53
(Figure 3G). While there are several peptides which exhibit
deuterium uptake differences outside of the error, the greatest
difference is 0.271 Da for a [M+2H]2+ peptide. As we see no
difference greater than 1 Da, the mass difference between a
hydrogen and deuterium atom, we can infer that there is no
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FIGURE 4 | nESI mass spectra of (A) 50µM N-terminal MDM2 (residues
1–126) sprayed from 50mM ammonium acetate + 0.5% DMSO. (B)
50µM N-MDM2 + Nutlin-3 in a 1:10 protein:ligand ratio, incubated for 30min
at room temperature. Final DMSO concentration 0.5%. Monomeric species
are denoted by single gray spheres, dimeric species by two gray spheres and
N-MDM2 bound to Nutlin-3 by a single gray sphere and small blue sphere.
significant structural difference between Np53 in the absence
and presence of RITA on the timescale of these experiments.
Our shortest time step (15 s) is insufficient to observe the
conformational changes occurring as the protein has enough
time to rearrange back to its original conformations. In contrast,
the isolated gas phase conformers exiting the electrosprayed
droplets appear trapped in distinct conformers at least over
the time scale of our IM-MS experiments. We estimate this
time to be ∼15ms including the transmission of ions to our
drift cell (McCullough et al., 2008), which is short enough to
retain the conformational changes induced by RITA such that
they can be observed. Both of the solution approaches indicate
conformational flexibility and some slight change in structural
content in the presence of the ligand, IM-MS provides a more
definitive readout of the modulation of conformation to Np53 in
the presence of RITA.
We can contrast the results observed for the RITA interaction
with Np53 with that for the well-studied drug candidate Nutlin-3
with MDM2. N-MDM2 presents with a wide CSD (5 ≤ z ≤ 14),
again suggesting a disordered protein. DT IM-MS shows that N-
MDM2 presents in the gas-phase in at least two conformational
families, potentially assignable to the previously reported “open”
and “closed” position of the lid mini-domain (Uhrinova et al.,
2005; Worrall et al., 2009, 2010). When incubated with Nutlin-3,
we observe a substantial CSD shift toward the lower charge states
which cannot be attributed to the effect of DMSO alone (Figure
S4), again suggesting some conformational effect conferred
by Nutlin-3 binding. We observe binding of Nutlin-3 to N-
MDM2 over three charge states, [M+5H]5+, [M+6H]6+, and
[M+7H]7+. As there is no binding to the more extended high
charge states, Nutlin-3 may only be able to bind N-MDM2
in a compact conformation, which is transferred to the gas
phase as low charge state complex. DT IM-MS analysis showed
that Nutlin-3 configures N-MDM2 into a more compact and
inflexible conformer. The [M+5H]5+ charge state retains both
conformational families upon Nutlin-3 binding, however the
larger conformer at DTCCSHe ∼1250 Å2 was greatly reduced.
For the [M+6H]6+ and [M+7H]7+ ions, Nutlin-3 binding
configures the protein into a single conformer with a narrow
DTCCSDHe, indicating less dynamics. This single conformational
family was centered at a DTCCSHe ∼1250 Å2 for [M+6H]6+,
corresponding to conformational family C2, and ∼1400 Å2 for
[M+7H]7+ corresponding to family X. We see loss of both
the C1 and X families for [M+6H]6+ and loss of C2 and U
for [M+7H]7+, suggesting much lower flexibility of the protein
when bound to Nutlin-3.
Interestingly, it appears as for Np53, that the ligand free
N-MDM2 in the IM-MS experiments also retains a “memory”
of its in solution Nutlin-3 bound state. DTCCSDHe of N-
MDM2, incubated with Nutlin-3 but in its apo-form, show
similar conformers than those which retain binding of Nutlin-
3 (Figure 5, bottom panels). This suggests that Nutlin-3 binds
a higher proportion of analyte molecules than we observe, but
is not retained fully during desolvation. The apo [M+5H]5+
species is not only compact, suggesting that it rearranges back
to the free N-MDM2 conformer, or that some of it arises from
a conformer in solution that is incapable of binding Nutlin-3.
The apo [M+6H]6+ and [M+7H]7+ remain in tight, single
conformational families, and a much lower proportion of the
Nutlin-bound N-MDM2 presents in the [M+5H]5+ charge state
(Figure 4) supporting our hypothesis that Nutlin-3 is unable to
bind as well to the very compact conformer C1. For the larger
conformational families, N-MDM2 seems unable to rearrange
back to its original conformations within the timescale of
desolvation and analysis.
Conclusions
Multiple techniques have been used to probe the binding of
small molecule inhibitors RITA and Nutlin-3 to N-terminal p53
(Np53) and N-terminal MDM2 (N-MDM2), respectively. Native
mass spectrometry of Np53 shows a shift in the CSD toward
the lower charge states and loss of the more extended charge
states upon incubation with RITA. IM-MS of Np53 reveals two
conformational families in the absence of RITA. Upon incubation
with RITA, Np53 is configured into a novel, more compact
conformer C0 with loss of the more extended conformational
family. We are able to retain this conformational tightening in
the gas-phase on the time scale of our DT IM-MS experiments,
even though we are unable to preserve the RITA:Np53 complex
in the gas phase. HDX-MS data highlights the disordered nature
of Np53, with no discernible conformations visible on a longer
timescale. Very little differences are noted between the deuterium
on-exchange of Np53 in the absence and presence of RITA, and
we are unable to locate RITA induced conformational changes.
The nESI mass spectrum of N-terminal MDM2 shows a wide
range of charge states (5 ≤ z ≤ 14) indicative of a disordered
protein (Testa et al., 2011; Beveridge et al., 2014). The bimodal
distribution suggests the protein may possess a more compact
and more extended conformer. Indeed, DT IM-MS results show
the protein presents as at least two conformational families at all
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FIGURE 5 | Collision cross section distributions (DTCCSDHe)
derived from arrival time distributions (ATDs) for N-MDM2 sprayed
from 50mM ammonium acetate (+ 0.5% DMSO) for the (A)
[M+5H]5+, (B) [M+6H]6+, and (C) [M+7H]7+ charge states. Top
panel represents N-MDM2, middle panel represents N-MDM2 bound to
Nutlin-3 and bottom panel represents N-MDM2 incubated with Nutlin-3
but in apo-form with no small molecule bound. Proteins were incubated
with Nutlin-3 in a 1:10 protein:ligand ratio, for 30min at room
temperature. CCSDs were taken at a drift voltage of 35V and are
normalized to the intensity of the ion species in the corresponding mass
spectrum however to allow greater visibility, the [M+5H]5+, [M+5H]5+
bound to Nutlin-3 and [M+7H]7+ bound to Nutlin-3 DTCCSDHe have
been magnified X10. Conformational families are depicted by colored
Gaussian curves; C1 (black), C2 (red), X (blue), and U (green).
charge states. Upon incubation with Nutlin-3, we observe ligand
binding to the forms of the protein that present to the gas phase
with low charge states [M+5H]5+, [M+6H]6+, and [M+7H]7+,
suggesting selective binding to a compact conformer of MDM2,
or possibly that more extended forms lose Nutlin-3 on transfer
to the gas phase. The bound species of MDM2 are compact at
all three charge states, with [M+6H]6+ and [M+7H]7+ forming
a single conformational family centered at a DTCCSHe of the
middle conformational family exhibited by apo-N-MDM2. These
conformational changes are likely retained by ions which lose the
bound Nutlin-3 molecule during desolvation, indicating that the
protein is unable to rearrange during the experiment. IM-MS is
presented as a promising technique able to track conformational
changes in unstructured proteins on a millisecond timescale.
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